Cadus Buy or Sell Recommendation

Macroaxis provides Cadus Corporation buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding Cadus positions. The advice algorithm takes into account all of Cadus Corporation available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from Cadus buy-and-hold prospective. Please see also Cadus Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with current analyst consensus

Investment Horizon

  

Risk Tolerance

  
Symbol
Execute Advice
Cadus Corporation -- USA Stock  

USD 1.25  0.01  0.81%

Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding Cadus Corporation is 'Buy'.
For the selected time horizon Cadus Corporation has a risk adjusted performance of 0.0658, jensen alpha of 1.24, total risk alpha of (1.68), sortino ratio of 0.0 and treynor ratio of 1.27
We provide buy or sell advice to complement the prevailing expert consensus on Cadus. Our dynamic recommendation engine makes use of multi - dimensional algorithm to analyze the company potential to grow using all technical and fundamental data available at the time. To make sure Cadus is not overpriced, please confirm all Cadus fundamentals including its EBITDA as well as the relationship between Cash Flow from Operations and Retained Earnings . Given that Cadus is a hitting penny stock territory we recommend to closely look at its Price to Earning.

Returns Distribution Density

Mean Return1.39Value At Risk-0.8065
Potential Upside2.4793Standard Deviation5.6412
 Return Density 
      Distribution 

Institutional Investors

Security TypeSharesValue
Messner Smith Theme Value Investment Management LtdCommon Shares2 K2 K
Messner Smith Theme Value Investment Management LtdCommon Shares2 K2 K
Messner Smith Theme Value Investment Management LtdCommon Shares2 K2 K

Cadus Greeks

α
Alpha over DOW
= 1.24 
βBeta against DOW= 1.09 
σ
Overall volatility
= 5.64 
 IrInformation ratio = 0.22 

Cadus Volatility Alert

Cadus Corporation exhibits very low volatility with skewness of 4.5 and kurtosis of 20.72. However, we advise investors to further study Cadus Corporation technical indicators to make sure all market info is available and is reliable.
    
 Better Than Average     
    
 Worse Than Average Compare Cadus to competition
FundamentalsCadusPeer Average
Return On Equity(1.8) % (15.17) %
Return On Asset(1.14) % (15.64) %
Current Valuation27.44 M152.14 B
Shares Outstanding26.29 M1.43 B
Shares Owned by Insiders0.09 % 6.91 %
Shares Owned by Institutions67.85 % 18.37 %
Price to Earning(36.54) times40.69 times
Price to Book0.61 times14.44 times
EBITDA(753.28 K)1.41 B
Net Income(736.73 K)517.71 M
Cash and Equivalents4.37 M3.89 B
Cash per Share0.17 times5.17 times
Current Ratio9.19 times3.3 times
Book Value Per Share1.55 times13.64 times
Cash Flow from Operations(3.08 M)1.25 B
Earnings Per Share(0.03) times2.3 times
Number of Employees510.67 K
Beta0.320.34
Market Capitalization31.55 M29.78 B
Total Asset41.5 M126.86 B
Retained Earnings(39.16 M)38.24 B
Working Capital40.89 M3.58 B
Current Asset41.29 M36.8 B
Current Liabilities399 K33.34 B
SellBuy
Buy

Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Currently Unavailable

Piotroski F Score

Financial Leverage

Inapplicable
Risk Adjusted Performance0.0658
Market Risk Adjusted Performance1.28
Mean Deviation2.41
Coefficient Of Variation407.07
Standard Deviation5.64
Variance31.82
Information Ratio0.2219
Jensen Alpha1.24
Total Risk Alpha(1.68)
Treynor Ratio1.27
Maximum Drawdown27.93
Value At Risk(0.81)
Potential Upside2.48
Skewness4.5
Kurtosis20.72

Current Valuation

Cadus Current Valuation Analysis
Cadus Corporation is rated below average in current valuation category among related companies. After adjusting for long-term liabilities, total market size of Biotechnology industry is now estimated at about 95.92 Billion. Cadus adds roughly 27.44 Million in current valuation claiming only tiny portion of stocks in Biotechnology industry.